Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett’s esophagus) in patient with chronic gastroesophageal reflux disease with or without other risk factors: introduction of two systematic reviews to inform a guideline of the Canadian Task Force on Preventiv e Health Care (CTFPHC) February 2019 KQ1: Benefits and Harms of screening Protocol registration : PROSPERO CRD 42017049993 Ottawa Evidence Review and Synthesis Centre: Candyce Hamel, Andrew Beck, Micere Thuku, Adrienne Stevens, Becky Skidmore, Beverley Sh ea, Brian Hutton, Julian Little, David Moher Knowledge Synthesis Group, Ottawa Methods Centre Ottawa Hospital Research Institute; School of Epidemiology and Public Health, University of Ottawa Ottawa, Ontario, Canada Clinical Experts & Collaborators: Avij it Chatterjee, The Ottawa Hospital Donna E. Maziak, The Ottawa Hospital Citation: Hamel C, Beck A, Thuku M, Stevens A, Skidmore B, Chatterjee A, Maziak D, Shea B, Hutton B, Little J, Moher D . 201 9 . Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett’s esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: systematic review to inform a guideline of the Canadian T ask Force on Preventive Health Care. Evidence Review Synthesis Centre: Ottawa Hospital Research Institute, Ottawa, Ontario. Available a t: https://canadiantaskforce.ca/guidelines KQ2: Patient Values and Preferences Protocol registration : PROSPERO CRD 42017050014 Ottawa Evidence Review and Synthesis Centre: Candyce Hamel, Andrew Beck, Adrienne Stevens, Becky Skidmore, Beverley J. Shea, Brian Hutton, Julian Little, David Moher Knowledge Synthesis Group, Ottawa Methods Centre Ottawa Hospital Research Institute; School of Epidemiology and Public Health, University of Ottawa Ottawa, Ontario, Canada Clinical Experts & Collaborators: Kristopher Dennis, The Ottawa Hospital Donna Maziak, The Ottawa Hospital Li se Bjerre, University of Ottawa Citation: Hamel C, Beck A, Stevens A, Skidmore B, Dennis K, Maziak D, Bjerre L, Shea B, Hutton B, Little J, Moher D. 201 9 . Patient values and preferences in relation to screening for esophageal adenocarcinoma and precancero us conditions (dysplasia and Barrett’s esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: systematic review to inform a guideline of the Canadian Task Force on Preventive Health Care. Evidence Review Syn thesis Centre: Ottawa Hospital Research Institute, Ottawa, Ontario. Available at: https://canadiantaskforce.ca/guidelines Canadian Task Force on Preventive Health Care Working Group Chair: Stéphane Groulx Canadian Task Force on Preventive Health Care Working Group Members: Scott Klarenbach, Harminder Singh, Brett Thombs, Brenda Wilson Public Health Agency of Canada Global Health and Guidelines Division: Marion Doull, Alejandra Jaramillo Garcia, Frances Gardiner, Heather Limburg, Wendy Martin Author contribution for KQ1 CH, AB, MT participated in the collection of data, data management and analyses for the review. CH drafted the review. BS developed the search strategy and provided text for the review. JL, DM, AS, BJS, BH, critically reviewed the review and provided methodological expertise. AC, DM reviewed the review and provided clinical expertise. Acknowledgements for KQ1 We would like to acknowledge the contribution of the following individuals: Raymond Daniel (managing citations), Doreen Whelan (screening of titles and abstract and full - text articles), Vesa Basha (screening full - text articles). We would also like to acknowledge the Canadian Task Force for Preventive Health Care membe rs and the external clinical experts, Drs. Targownik and Belletrutti who critically reviewed the manuscript and provided clinical expertise . Author contribution for KQ2 CH and AB participated in the collection of data, data management and analyses for the review. CH drafted the review. BS developed the search strategy and provided text for the review. JL, DM, AS, BJS, BH, critically reviewed the review and provided methodological expertise. KD, DM, LB reviewed the review and provided clinical expertise. A cknowledgements for KQ2 We would like to acknowledge the contribution of the following individuals: Raymond Daniel (managing citations). We would also like to acknowledge the Canadian Task Force for Preventive Health Care members and the external clinical experts, Drs. Targownik and Belletrutti who critically reviewed the manuscript and provided clinical expertise. Declaration of funding Funding for this systematic review was provided by the Public Health Agency of Canada, with funds distributed by the No va Scotia Health Research Foundation. This funding supported the development of the protocol, execution of search strategies, collection of the data, data management, analyses, and writing of the systematic review technical report. Role of funder The funder provided feedback on the protocol and draft systematic review, but was not involved in the study selection, data extraction, or analysis and were not involved in a decision to seek publication. Contents Abbreviations/Glossary ................................ ................................ ................................ ............... i Chapter 1 ................................ ................................ ................................ ................................ .... 1 1 Introduction ................................ ................................ ................................ .......................... 1 1.1 Background ................................ ................................ ................................ ................... 1 1.2 Object ive ................................ ................................ ................................ ....................... 4 Chapter 2: Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett’s esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: systematic review to inform a guideline of the Canadian Task Force on Preventive Health Care ................................ ................................ ................................ ................ 6 Abstract ................................ ................................ ................................ ................................ ... 6 2 KQ1 Methods ................................ ................................ ................................ ................... 8 2.1 Analytic Framework for EAC Screening ................................ ................................ ........ 8 2.2 Research Key Questions ................................ ................................ ................................ 8 2.3 Inclusion and Exclusion Criteria ................................ ................................ .................... 8 2.4 Literature Search ................................ ................................ ................................ ......... 10 2.5 Study Selection ................................ ................................ ................................ ............ 11 2.6 Data extraction and management ................................ ................................ ................. 11 2.7 Risk of Bias (ROB) Assessment ................................ ................................ .................. 11 2.8 Analysis ................................ ................................ ................................ ....................... 12 2.9 Amendments to the protocol ................................ ................................ ........................ 12 3 Results ................................ ................................ ................................ ............................... 13 3.1 Summary of the Literature Search ................................ ................................ ................ 13 3.2 Results for Key Question 1a ................................ ................................ ........................ 14 3.3 Re sults for Key Question 1b ................................ ................................ ........................ 23 4 Discussion ................................ ................................ ................................ .......................... 24 4.1 Implications for Research ................................ ................................ ............................ 26 5 Conclusion ................................ ................................ ................................ ......................... 27 Chapter 3: Patient values and preferences in relation to screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett’s esophagus) i n patients with chronic gastroesophageal reflux disease with or without other risk factors: systematic review to inform a guideline of the Canadian Task Force on Preventive Health Care ................................ .............. 28 Abstract ................................ ................................ ................................ ................................ .... 28 6 KQ2 Methods ................................ ................................ ................................ ..................... 30 6.1 Analytic Framework for EAC Screening ................................ ................................ ...... 30 6.2 Research Key Questions ................................ ................................ .............................